Taipei's Bora wants in on the CDMO game as report shows plenty of room for industry growth

Josh Sullivan

Taipei’s Bora Pharmaceuticals has linked up with Taishin Healthcare to invest about $108 million into CDMOs and CROs in response to a booming business environment …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Taipei's Bora wants in on the CDMO game as report shows plenty of room for industry growth

Josh Sullivan

Sign up to read this article for free.

A rare neurological disease is Sage’s last, best hope after failures in depression

Novartis strikes radiopharma deal with Ratio worth up to $745M

Rocket shares promising long-term results from rare heart disease gene therapy in small study

FDA offers more guidance on developing cell and gene therapies

Scottish biotech debuts with ‘Trojan horse’ platform for cancer

Are programs with compounded GLP-1s safe for your population?

Taipei's Bo­ra wants in on the CD­MO game as re­port shows plen­ty of room for in­dus­try growth

Josh Sullivan

Sign up to read this article for free.

A rare neu­ro­log­i­cal dis­ease is Sage’s last, best hope af­ter fail­ures in de­pres­sion

No­var­tis strikes ra­dio­phar­ma deal with Ra­tio worth up to $745M

Rock­et shares promis­ing long-term re­sults from rare heart dis­ease gene ther­a­py in small study

FDA of­fers more guid­ance on de­vel­op­ing cell and gene ther­a­pies

Scot­tish biotech de­buts with ‘Tro­jan horse’ plat­form for can­cer

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Taipei's Bora wants in on the CDMO game as report shows plenty of room for industry growth

A rare neurological disease is Sage’s last, best hope after failures in depression

Novartis strikes radiopharma deal with Ratio worth up to $745M

Rocket shares promising long-term results from rare heart disease gene therapy in small study

FDA offers more guidance on developing cell and gene therapies

Scottish biotech debuts with ‘Trojan horse’ platform for cancer

Are programs with compounded GLP-1s safe for your population?